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Abstract
Prostate cancer (PCa) patients receive androgen-deprivation therapy (ADT) to reduce tumor burden. However, com-
plete eradication of PCa is unusual, and recurrent disease is evident within approximately 2 years in high-risk patients.
Clinical evidence suggests that combining ADT with radiotherapy improves local control and disease-free survival in
these patients compared with radiotherapy alone. We investigated whether vascularization of androgen-sensitive PCa
xenografts changed after ADT and whether such therapy affected radiation response. CWR22 xenografts received
combinations of ADT by castration (CWR22-cas) and 15 Gy of single-dose irradiation. At a shortest tumor diameter
of 8 mm, vascularization was visualized by dynamic contrast-enhanced magnetic resonance imaging before radiation
and 1 and 9 days after radiation. Voxel-wise quantitative modeling of contrast enhancement curves extracted the he-
modynamic parameter K trans, reflecting a combination of permeability, density, and blood flow. Tumor volumes and
prostate-specific antigen (PSA) were monitored during the experiment. The results showed that K trans of CWR22-cas
tumors 36±4days after ADTwas 47.1%higher thanK trans of CWR22 tumors (P= .01). CWR22-cas tumors showed no
significant changes in K trans after radiation, whereas K trans of CWR22 tumors at day 1 decreased compared with pre-
treatment values (P = .04) before a continuous increase from day 1 to day 9 followed (P = .01). Total PSA in blood
correlated positively to tumor volume (r = 0.59, P < .01). In conclusion, androgen-exposed xenografts demonstrated
radiation-induced reductions in vascularization and tumor volumes, whereas androgen-deprived xenografts showed
increased vascularization and growth inhibition, but no significant additive effect of radiation.
Neoplasia (2010) 12, 818–825
Abbreviations: ADT, androgen-deprivation therapy; DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; PCa, prostate cancer; PSA, prostate-specific antigen;
ROI, region of interest; RT, radiotherapy; TE, echo time; TR, repetition time; VIF, vascular input function
Address all correspondence to: Kathrine Røe, MSc, Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, 0310 Oslo, Norway.
E-mail: Kathrine.Roe@rr-research.no
1This work was financially supported by the South-Eastern Norway Regional Health Authority grant 2009070 (K.R.) and the Norwegian Cancer Society grant 80114001 (T.S.).
Received 26 March 2010; Revised 21 June 2010; Accepted 22 June 2010
Copyright © 2010 Neoplasia Press, Inc. All rights reserved 1522-8002/10/$25.00
DOI 10.1593/neo.10484
www.neoplasia.com
Volume 12 Number 10 October 2010 pp. 818–825 818
Introduction
Androgens are the primary regulators of prostate cancer (PCa) growth
and proliferation [1]. The effects of androgen-deprivation therapy
(ADT) on prostatic carcinoma are significant, particularly for clinically
localized disease [2]. ADTresults in a reduction of tumor cells due to a
shift to quiescence and apoptosis [3,4]. Although ADT effectively
causes dormancy and reduced tumor burden, complete eradication
of PCa rarely occurs and biochemical progression in high-risk PCa
patients receiving ADT is usually evident within 2 years. The mecha-
nisms preceding the transition from the androgen-sensitive to the in-
curable androgen-resistant state of PCa are still not fully understood.
Although PCa are not considered to be highly vascular tumors, they
demonstrate increased vascular endothelial growth factor expression
and increased vascularization when compared with benign prostatic
hyperplasia and normal prostatic tissue [1]. It has also been shown that
androgens are involved in blood flow regulation in vivo and that an-
drogen withdrawal affects vascular endothelial growth factor expression,
microvessel density, and permeability in these tumors [1,5]. However,
the vascular remodeling after ADTremains unclear and warrants further
investigations. In this regard, noninvasive measurements are beneficiary
to allow monitoring of changes in tumor vascularization.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) allows repeated, in vivo visualization of tumor vasculature and is
thus important in clinical response monitoring of increased or inhibited
angiogenesis [6]. By applying quantitative pharmacokinetic modeling of
the contrast agent uptake in tumor tissue, vascular kinetic biomarkers
associated with underlying physiological processes can be derived; such
markers may further be used in monitoring response to treatments and
characterizing tumors [7]. One of the parameters that can be deduced
from such modeling, the forward volume transfer constant between
blood plasma and extravascular extracellular space, K trans, has shown
to reflect acute treatment-induced changes in tumor vascularization [8].
Radiotherapy (RT) is an important treatment modality for PCa, al-
though its efficacy decreases with stage. Clinical trials have shown that
the combination of neoadjuvant or adjuvant ADTwith RT improves
local control and disease-free survival for PCa patients compared with
RT alone, especially for high-risk patients [2,9]. However, there are
also evidences for the contrary, and the possibility that ADT deteriorates
the tumor vascularization, thus induces increased hypoxia and reduced
effect of subsequent RT, should also be considered. Technological ad-
vances of RT equipment have brought intensity-modulated RT and
high–dose rate brachytherapy into the clinic, allowing increased tumor
doses. These techniques rely on noninvasive imaging for accurate tumor
localization;moreover, advanced imaging techniquesmay provide useful
information about tumor biologic and physiological factors of impor-
tance to the response to therapy. In this regard, DCE-MRI represents
a promising technique that has the potential of providing information
about the vascularization and oxygenation in tumors and may become
useful in the evaluation of RTresponse for PCa patients.
The specific aims of the present study were to apply DCE-MRIwith
subsequent pharmacokinetic analysis to investigate whether vasculari-
zation in human androgen-sensitive CWR22 PCa xenografts alters
after ADT by castration and whether ADT affects radiation response.
Materials and Methods
Animals and Xenografts
Male, sexually mature BALB/c nude mice (30-35 g, 6-8 weeks old)
were used in this study. The Institutional and National Committee on
Research on Animal Care approved the protocol, and the experiment
was performed according to Interdisciplinary Principles and Guidelines
for the Use of Animals in Research, Marketing and Education (New
York Academy of Science, New York, NY). The mice were bred at the
animal department of our institute and kept under specific pathogen-
free conditions at constant temperature (21.5-22.5°C) and humidity
(50%-60%) and given sterilized food and water ad libitum.
Xenografts were generated by subcutaneous (s.c.) implantation of
∼(2 × 2 × 2) mm3 tumor tissue from the human androgen-sensitive
CWR22 xenograft into one flank of each mouse. Procedures for im-
plantation, growth, and harvesting of CWR22 xenografts in mice were
followed according to previous reports [10,11]. Animals with CWR22
xenografts were included into the experiment when their shortest tumor
diameter reached 8 mm. Androgen-deprived CWR22 xenografts, de-
noted CWR22-cas, were obtained by castration of animals bearing
CWR22 xenografts. The surgical castration was performed at a shortest
tumor diameter of 13 mm, and the animals were included into the ex-
periment when the CWR22-cas xenografts had regressed to a shortest
tumor diameter of 8 mm. The time from castration to inclusion was
36 ± 4 days. At the day of inclusion, a pretreatment (day 0) MRI was
performed before each of the two groups of 16 animals (androgen-
exposed and androgen-deprived) was divided into two subgroups of
8 animals: radiation and control. The tumors in the radiation groups
were irradiated after the day 0 MRI. At days 1 and 9, repeated MRIs
were performed on all animals in the experiment.
Thirty-two animals were randomly allocated into four groups of eight
animals: CWR22 control (CWR22-C), CWR22 irradiation (CWR22-
IR), CWR22-cas control (CWR22-cas-C), and CWR22-cas irradiation
(CWR22-cas-IR). For the CWR22 groups, all animals were killed when
the longest tumor diameter of two of the tumors in the group reached
16 mm. Animals with CWR22-cas tumors were killed 30 days after
inclusion into the experiment.
To determine the mean vascular input function needed in pharmaco-
kinetic modeling of contrast enhancement curves, eight separate tumor-
bearing, male mice with identical weight and age as the other 32 animals
were subjected to left cardiac ventricular DCE-MRI examinations.
In addition, six CWR22 tumors of the same size (diameter = 8 mm)
were used in immunohistochemistry to assess differences in tumor
vascularization, perfusion, and hypoxia between individual tumors.
Tumor Volume
Tumor volumes were estimated from caliper measurements from im-
plantation until the end of the experiment using the formula (length ×
length × width) / 2, with length being the longest diameter across the
tumor and width being the corresponding perpendicular diameter.
Radiotherapy
Tumors in the two radiation groups received a single dose of 15 Gy
on day 0 (after preradiation MRI) using a 60Co source (Mobaltron 80;
TEM Instruments, Crawley, UK) with a dose rate of 0.8 Gy/min.
Anesthesia and Analgesia
Animals were anesthetized with s.c. injections of a mixture of
2.4 mg/ml tiletamine and 2.4 mg/ml zolazepam (Zoletil vet; Virbac
Laboratories, Carros, France), 3.8mg/ml xylazine (Narcoxyl vet; Roche,
Basel, Switzerland), and 0.1 mg/ml butorphanol (Torbugesic; Fort
Dodge Laboratories, Fort Dodge, IA), diluted 1:5 in sterile water. A dose
of 50 μl/10 g of body weight was administered before radiation, and
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75 μl/10 g of body weight was administered before MRI acquisitions
and castration. Analgesia was provided to castrated animals by s.c.
injections of buprenorphine (Temgesic; Schering-Plough, Brussels,
Belgium) in a dose of 0.1 mg/kg.
DCE-MRI Acquisition
DCE-MRI of the tumors’ central slice was acquired at day 0 (before
radiation), day 1 (24 hours after radiation), and day 9 using a 1.5-TGE
Signal LS clinical scanner (GE Medical Systems, Milwaukee, WI).
Weight of individual animals determined the amount of contrast agent
(Gd-DTPA; Magnevist, Schering, Berlin, Germany; diluted in hepa-
rinized saline to 0.06 M) to be administrated. Before MRI, a heparin-
ized 24-gauge catheter attached to a cannula containing 0.01 ml/g
body weight saline-diluted Gd-DTPA was inserted into the tail vein.
The animals were placed in a special cradle and put into an in-house
builtMRmouse coil [12] before the coil was placed in the scanner. The
animals’ temperature was maintained at 38°C during the acquisition.
MRI included axial fast spin-echo T2-weighted images (echo time
[TEeff ] = 85 milliseconds, repetition time [TR] = 4000 milliseconds,
echo train length = 16, image matrix = 256 × 256, field of view
(FOV) = 4 cm, slice thickness = 2 mm) to localize tumor, and dynamic
fast spoiled gradient-recalled T1-weighted images (TE = 3.5 milli-
seconds, TR = 180 milliseconds, image matrix = 256 × 128, FOV =
6 cm, slice thickness = 2 mm, flip angle (FA) = 80°) to investigate con-
trast kinetics. After five precontrast images, Gd-DTPA was manually
injected during 3 seconds before continuing dynamic postcontrast imag-
ing for 20 minutes with 12-second time resolution. Reconstructed voxel
size of T1-weighted images was 0.23 × 0.47 × 2 mm3. Corresponding
proton density images (TE = 3.5 milliseconds, TR = 360 milliseconds,
image matrix = 256 × 128, FOV = 6 cm, slice thickness = 2 mm, FA =
10°) were acquired before and after DCE-MRI.
Mean vascular input functions (VIFs) were obtained fromDCE-MRI
of the left cardiac ventricle in eight separate male mice. The imaging
protocol was identical to the one previously mentioned except for TR =
200milliseconds for the proton density images and TR = 80milliseconds
and image matrix = 512 × 256 for the T1-weighted images (voxel size,
0.11 × 0.23 × 2 mm3). T1-weighted imaging consisted of 120 post-
contrast images acquired every 10 seconds. Cardiac gating was not used
for VIFmeasurements; thus, tominimizemotion artifacts from cardiac
pulsation, mice were placed in the prone position, and phase encoding
was applied in the R/L direction. The region of interest (ROI) was cen-
tered well within the left cardiac ventricle to ensure that the ROI, at all
time points during the cardiac cycle, was within the cardiac ventricle.
DCE-MRI Analysis
DCE-MRI analysis was performed using in-house written programs in
IDL (Interactive Data Language v6.2; Research Systems, Inc, Boulder,
CO). Gd-DTPA concentrations were calculated from signal intensities
and proton density images using the method of Hittmair et al. [13].
Individual VIFs were determined by fitting a biexponential function to
concentration curves from the left cardiac ventricle according to VIF =
Aexp(−Bt) +Cexp(−Dt), withA andB representing the equilibration of
Gd-DTPA between plasma and extracellular space,C andD represent-
ing kidney clearance of Gd-DTPA, and (A + C )−1 (L/kg) representing
plasma volume of the mouse per unit of body weight. A representative
VIF with fitted function is shown in Figure 1. Mean VIFs for the
eight mice were described by the following four parameters: A = 3.57 ±
0.34 mM, B = 0.025 ± 0.005/s, C = 1.45 ± 0.15 mM, andD = 0.0074 ±
0.0036/s. ThisVIFwas assumed to be valid for allmice in the experiment.
An ROIwas manually delineated around the tumor in T1-weighted
images, excluding surrounding skin and connective tissue. Using the
mean VIF parameters and contrast enhancement curves for individual
voxels within the selected ROI, each voxel was fitted to the model
of Tofts et al. [8]. Two representative contrast enhancement curves
of regions with low and high contrast uptake, respectively, and the
corresponding fitted Tofts functions are shown in Figure 2A. This
allowed voxel-by-voxel estimations of the forward volume transfer
Figure 1. VIF showing left cardiac ventricle contrast enhancement
as function of time after intravenous administration of Gd-DTPA.
Dots represent acquired raw data and the solid line represent
the fitted biexponential function.
Figure 2. Representative contrast enhancement raw data curves
(dots) of regions with low and high contrast uptake, respectively, with
corresponding fitted Tofts functions (solid lines) (A). Example of a con-
trast enhancement curve in a pixel that could not be fitted to the Tofts
model (B).
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constant for Gd-DTPA between blood plasma and the extravascular
extracellular space, K trans (s−1), across the tumor.
When performing Tofts modeling, not all voxels present biologically
valid values of K trans. For some voxels, the fit fails to converge because
of low Gd-DTPA uptake or because modeling returns negative K trans
values. An example of a contrast enhancement curve from a voxel that
cannot be fitted to the Tofts model is shown in Figure 2B. All these
unfitted voxels were set equal to 0 and included in K trans maps and
in calculation of mean tumor K trans. The fraction of unfitted voxels,
scored as the sum of unfitted voxels versus the total number of voxels
within the tumor ROI, was monitored to investigate the possible link
between this fraction and nonviable tumor regions.
Prostate-Specific Antigen
Blood for prostate-specific antigen (PSA) analysis was collected from
each animal at days 0, 1, and 9 and at the time of killing. Blood samples
were allowed to coagulate before being centrifuged and frozen at −80°C
until analysis. Free and total PSAwere assayed using the fluoroimmuno-
metric AutoDELFIA ProStatus PSA Free/Total kit (PerkinElmer Life
and Analytical Sciences, Wallac Oy, Turku, Finland).
Immunohistochemistry
Hypoxia was determined by injecting 80 mg/kg pimonidazole hy-
drochloride (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole
hydrochloride; Natural Pharmaceuticals, International Inc., Research
Triangle Park, NC) in 0.5 ml of saline intraperitoneally (i.p.) 60 min-
utes before killing the animals. Five minutes before killing the ani-
mals, 15 mg/kg Hoechst 33342 (Sigma Chemical Co, St Louis, MO)
in 0.1ml of saline was injected intravenously for determination of tumor
perfusion. Immediately after dissection, tumors were frozen in liquid
nitrogen and stored at −80°C until they were shipped to the Depart-
ment of Radiation Oncology, Radboud University, Nijmegen Medical
Center, Nijmegen, The Netherlands, for staining and imaging.
The central slice of the tumor was cut before staining and scanned
according to procedures described previously [14] to obtain triple im-
munofluorescent images of tumor vasculature (9F1; TCL image,
TNO, Delft, The Netherlands), blood perfusion (Hoechst), and
hypoxia (pimonidazole).
Quantitative analysis of immunohistochemistry was performed us-
ing an in-house written program inMATLAB 7.0.1 (TheMathWorks,
Natick, MA). The tumor area, excluding artifacts and tissue folding,
was manually identified and delineated using GIMP 2.6.4 (www.
gimp.org). Pimonidazole and Hoechst stains were segmented by ap-
plying a threshold at 0.3 × 95th intensity percentile and labeled as hyp-
oxic and perfused, respectively. The hypoxic fraction was calculated as
the total number of hypoxic pixels divided by the total number of pix-
els in the tumor area. Vessel density was quantified as the total number
of vessels, irrespective of vessel area, divided by the total tumor area. A
vessel was defined as perfused if at least half of the vessel’s pixels were
within two pixels’ rectilinear distance (5.18 μm) from a perfusion-
stained pixel. Hypoxic distance histograms were calculated using the
euclidean norm along the shortest straight line from each hypoxic pixel
to its nearest vessel, irrespective of tumor boundaries.
Statistical Analysis
Statistical analysis was performed using SPSS 16.0 (SPSS, Cary,
NC). Differences between groups and time points were analyzed using
two-sided t tests under conditions of normality. Pearson correlation
test analyzed whether correlations between variables were significant.
Results are presented as mean ± SEM, and a significance level of 5%
was used in all statistical analyses.
Results
Tumor Growth
Pretreatment tumor volumes were normally distributed (P = .60) with
a mean tumor volume of 392.1 ± 37.7 mm3. Figure 3 shows normalized
tumor volumes for control and irradiated CWR22 and CWR22-cas
tumors.
Exponentially growing CWR22-C tumors showed a 2.5-fold in-
crease (P < .01) from day 0 to day 9. At the completion of the study,
volumes of these tumors had increased 9.6-fold compared with base-
line. Radiation induced an initial 0.3-fold (P < .01) tumor volume
decrease in CWR22-IR tumors from day 0 to day 1, followed by a
1.3-fold increase in tumor volume from day 1 to day 9. CWR22-IR
tumors showed growth inhibition before slowly relapsing from day 51
and onward. At day 30, mean normalized tumor volumes of CWR22-C
tumors were 12-fold larger (P < .01) than tumor volumes of CWR22-IR
tumors (Figure 3).
Volumes of tumors in the CWR22-cas cohorts decreased contin-
uously during follow-up of the experiment. Thirty days after initiation
of the study, volumes of CWR22-cas-C and CWR22-cas-IR tumors
had decreased to 0.6-fold (P < .01) and 0.4-fold (P < .01) of pretreat-
ment values, respectively.
Figure 3. Tumor volumes of CWR22 (A) and CWR22-cas (B) normal-
ized today0 (dayof inclusion). Each timepoint representsnormalized
mean and SEM values. C, control tumors; IR, irradiated tumors
receiving a single fraction of 15 Gy after the MRI at day 0.
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Except for day 1, where CWR22-IR tumors showed an immediate
radiation-induced reduction in tumor volume (P = .03), there were
no significant differences in tumor growth between CWR22-IR tu-
mors and androgen-deprived CWR22-cas-C tumors throughout the
experiment.
Prostate-Specific Antigen
Figure 4A shows total PSA measured in the four groups at days 0,
1, and 9 and at the day of killing. Mean pretreatment total PSA was
30.7 ± 6.0 ng/ml for animals bearing CWR22 tumors, whereas total
PSA for animals bearing CWR22-cas tumors was 18.3 ± 3.2 ng/ml.
For animals bearing CWR22-C tumors, total PSA increased to 88.2 ±
12.5 ng/ml (P < .01) and 212.4 ± 13.8 ng/ml (P < .01) after 9 days and
at the end of the experiment, respectively. For comparison, total PSA
measured in animals with CWR22-IR tumors was 50.5 ± 10.7 ng/ml
(P = .02) at day 9 and 75.8 ± 17.4 ng/ml (P = .02) at the completion of
the experiment. In animals bearing CWR22-cas tumors, total PSAwas
reduced on all subsequent measurement days, with the decrease from
day 9 to the end point being significant for both CWR22-cas-C
(63.3% decrease, P < .01) and CWR22-cas-IR animals (94.3% de-
crease, P = .01). It was a positive correlation between total PSA and
tumor volume (r = 0.59, P < .01; Figure 4B). The correlation was
stronger for animals with CWR22 tumors (r = 0.74, P < .01) than
for animals with CWR22-cas tumors (r = 0.27, P = .03). The correla-
tion between total PSA and tumor volume was strong for both
CWR22 and CWR22-cas tumors when only subjecting control tu-
mors to analysis (r = 0.74, P < .01 and r = 0.73, P < .01, respectively).
Qualitative Assessment of DCE-MRI
An example of an anatomic T1-weighted MR image through the
center of a CWR22 tumor and matched slice of K trans is shown in
Figure 5A. The black areas within the tumor ROI are unfitted voxels.
Rapid contrast agent uptake was detected in the dynamic T1-weighted
MR images in the peripheral regions of the tumors, whereas signal en-
hancement in central regions was slower. Within 20 minutes after con-
trast agent administration, washout of contrast agent was manifested for
all tumors; however, precontrast signal intensity levels were not restored.
Treatment Monitoring Using DCE-MRI
Figure 5B shows pretreatment, day 1, and day 9 K trans maps of
a CWR22-IR tumor, whereas Figure 6 summarizes the mean tumor
K trans of all tumors. The mean pretreatment K trans value was 47.1%
higher for CWR22-cas tumors compared with CWR22 tumors (P =
.01). After radiation, K trans of CWR22-cas-IR tumors was unchanged
when comparing with pretreatment values. Furthermore, there were no
significant differences inK trans between irradiated and control CWR22-
cas tumors at day 1 or day 9. ForCWR22-IR tumors,K trans was reduced
by 45.7% from day 0 to day 1 (P = .04), followed by an 87.7% increase
from day 1 to day 9 (P = .01). No significant day-to-day variations were
found for the CWR22-C tumors.
The decrease in K trans from day 0 to day 9 for CWR22-C tumors
coincided with a 38.6% increase in the fraction of unfitted voxels, giv-
ing a significant negative correlation between K trans and the fraction of
unfitted voxels for this group (r = −0.79, P < .01). Table 1 shows the
fraction of unfitted voxels within each group at the time points for
DCE-MRI.
Discussion
The present study shows that tumor vascularization is different in
androgen-sensitive CWR22 xenografts under androgen-exposed
and androgen-deprived conditions and that the resulting PCa pheno-
types have different response to radiation.
CWR22-cas tumors had significantly higher mean K trans than
CWR22 tumors of the same size in noncastrated animals. Several stud-
ies have reported decreased vascularization and angiogenesis after
surgical or chemical ADT. These studies have examined vasculariza-
tion responses immediately or within a few days after ADT. In our
study, we investigated vascularization after a longer period of androgen-
deprivation (36 ± 4 days), which, when the five-times faster metabo-
lism in mice is accounted for, corresponds to approximately 6 months
in humans. This period is the same as many PCa patients receive ADT
before RT treatment is initiated. Because of the controversial use of
RT as an additional treatment at this time point, and also the uncer-
tainties about the required duration of ADT before RT, we wanted to
investigate this more clinically relevant time point, rather than the im-
mediate androgen-deprivation effect. So even if volumes of CWR22-cas
Figure 4. Total PSA in blood (mean ± SEM) at days 0, 1, and 9 and
at the end of the experiment for the four treatment groups (A).
C, control tumors; IR, irradiated tumors receiving a single fraction
of 15 Gy after the MRI at day 0. Total PSA in blood correlated pos-
itively to tumor volume (r = 0.59, P < .01) (B). Separating CWR22
and CWR22-cas tumors, the correlation between total PSA and tu-
mor volume was stronger for animals with CWR22 tumors (r =
0.74, P < .01) than for animals with CWR22-cas tumors (r =
0.27, P = .03).
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tumors regressed, our MRI findings indicate an increasing tumor vas-
cularization, when compared with exponentially growing CWR22 tu-
mors with identical tumor volumes at the time of MRI examination.
CWR22-IR tumors showed a significant decrease in K trans 1 day
after receiving a single radiation dose of 15 Gy, which might result
from radiation-induced reductions in blood flow, endothelial surface
area, and/or vessel permeability. Together, these factors contribute to
compromised inflow of contrast agent, thereby leading to slowly or
nonenhancing regions in DCE-MRI and reduced tumor K trans. We
hypothesize that this decreased K trans might be related to increased
hypoxia. Because animals were imaged repeatedly (days 0, 1, and 9)
and posttreatment differences in tumor growth were assessed, possible
relations between K trans and hypoxia were investigated in a separate
experiment involving immunohistochemistry of six additional xeno-
grafts. In Figure 7, triple immunofluorescent images of tumor tissue
sections from two tumors with substantially different hypoxic patterns
are shown. The tumor in Figure 7A has an equally distributed hypoxic
pattern, as opposed to the more extensive and centrally distributed hyp-
oxic pattern surrounding blood vessels in Figure 7B. The hypoxic frac-
tion was 28.1% in the left tumor and 45.3% in the right tumor, and
the hypoxic distance histogram (Figure 7C ) visualizes the differences in
distances between hypoxia and vessels. The tumor with the highest
Figure 6. K trans (mean ± SEM) values before radiation and 1 and
9 days after radiation. The two bars on day 0 represent pretreatment
groups for 16 CWR22 tumors and 16 CWR22-cas tumors. After the
day 0 MRI, each of the two groups of 16 animals was divided into
two subgroups of eight animals: radiation and control. The four bars
on days 1 and 9 refer to these four subgroups. C indicates control
tumors; IR, irradiated tumors receiving a single fraction of 15 Gy af-
ter the MRI at day 0.
Table 1. Fraction of Unfitted Voxels from Pharmacokinetic Modeling.
Day 0 (%) Day 1 (%) Day 9 (%)
CWR22
Control 17.5 ± 6.0 14.9 ± 4.4 24.2 ± 3.2
Irradiated 12.6 ± 3.2 34.0 ± 7.2* 17.1 ± 3.2†
CWR22-cas
Control 16.9 ± 3.3 17.5 ± 3.1 19.7 ± 2.9
Irradiated 13.4 ± 5.8 14.7 ± 6.0 25.5 ± 7.8
The fraction of unfitted voxels from pharmacokinetic modeling of DCE-MRI data for each group at
the three imaging time points.
*The increase in the fraction of unfitted voxels from day 0 to day 1 in CWR22-IR tumors was sig-
nificant (P = .02).
†The decrease in the fraction of unfitted voxels from day 1 to day 9 in CWR22-IR tumors was close to
significant (P = .06).
Figure 5. Anatomic T1-weightedMR image through the center of a CWR22 tumor with illustration of the delineation of tumor ROI, and the
corresponding K trans map within the selected ROI. The black areas within the tumor ROI are unfitted voxels (A). K trans (× 10−3 s−1) maps
and mean values of a CWR22 tumor before radiation (day 0) and after radiation (days 1 and 9) (B).
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hypoxic fraction, where hypoxia confined the vessels, demonstrated a
lower K trans value (0.0084 ± 0.0004 × 10−3 s−1) than the less hypoxic
tumor (0.0184 ± 0.0004 × 10−3 s−1). These two images illustrate that
the appearance and amount of hypoxia might be the cause of altered
K trans values. In addition, the presence of hypoxia is a well-known fac-
tor of significant importance in PCa, by promoting tumor progression
and impairing treatment responses [15].
In contrast to the poorly vascularized androgen-exposed CWR22 tu-
mors, irradiation of the well-vascularized androgen-deprived CWR22-
cas tumors did not significantly alter theK trans values.Whereas oxygen
consumption depends on the cells’ respiratory activity and cell den-
sity, the oxygen supply is primarily determined by blood perfusion
and microvascular density [16]. Thus, the high K trans values of the
androgen-deprived tumors are anticipated to be related to increased
tumor oxygenation, which is a beneficiary condition in RT response.
An open phase 3 study recently showed that patients with androgen-
sensitive PCa receiving 3 months of ADT before combined ADTand
RT halved the PCa-specific mortality and decreased the risk of PSA
relapse relative to those receiving ADT alone [2].
In our study, radiation did not represent an additive effect on growth
inhibition of androgen-deprived CWR22-cas tumors. The dominat-
ing effect of ADTalone on growth inhibition might have marginalized
the contribution of radiation to the overall effect. Moreover, killing the
animals in the androgen-deprived groups 30 days after initiation of
ADT could have been too early, thereby missing the opportunity to
resolve an enhanced effect of the combination of ADT and RT over
RTonly.
The unfitted voxels from the pharmacokinetic modeling of contrast
uptake in tumor tissue were set to 0 and included in the calculation of
mean tumor K trans. It has previously been shown that the fraction
of unfitted voxels is strongly correlated to tumor necrosis, and consis-
tent with this, exclusion of fit failures from mean tumor K trans calcu-
lation eliminates this correlation [17]. Thus, by excluding unfitted
voxels, K trans is essentially determined from the viable tumor tis-
sue, excluding necrotic hypoperfused regions. Bradley et al. [17] and
Galbraith et al. [18] proposed that these posttherapy low-enhanced
voxels can be a useful noninvasive biomarker of tumor necrosis, pro-
viding support for including these voxels in our K trans calculations.
The largest increase in the fraction of unfitted voxels was found in
the tumors responding to treatment (CWR22-IR), reflected by reduced
tumor K trans and reduced tumor volumes. Thus, we hypothesize that
necrosis might the major factor determining this fraction. However, be-
cause we performed longitudinal MRI of all tumors, tumor histology
with quantification of necrosis could not be obtained simultaneously,
and thus, the validity of this hypothesis requires further investigations
in a separate study.
The model of Tofts and Kermode assumes the contrast agent to be
instantly mixed in the plasma. In our experimental study, this as-
sumption is reasonable as the blood circulation time in mice is short
relative to the injection time. The use of K trans as a measure of vas-
cularization also assumes that blood flow is not flow limited and that
flow is always greater than permeability [8]. Thus, especially for large
tumors with necrotic cores or irradiated tumors, precaution should be
taken when analyzing and interpreting results. However, much of the
low-flow areas in the center of the tumors were unfittable, and thus,
this is taken into account by including these voxels in the mean tumor
K trans calculations.
We found that total PSA in CWR22 xenografts was positively cor-
related to tumor volumes. Furthermore, blood levels of PSA were de-
creasing after ADT. This is in accordance with findings from other
groups using CWR22 xenografts in preclinical studies [10,19]. The
use of functional imaging technologies, such as positron emission to-
mography (PET) and MRI, has revealed that changes in tumor biol-
ogy and physiology precede changes in PSA. The rapid postradiation
decrease of K trans in our CWR22 tumors did not coincide with de-
creased PSA values, suggesting the possibility of using K trans as an early
predictor of treatment response. Rather than showing reduced PSA
values, the CWR22 tumors demonstrated a slow increase after radia-
tion. This has also been shown by others [19] and can be explained by
the low time resolution of PSA measurements with the possibility of
missing an eventual transient decrease in PSA. However, the increase
in K trans of CWR22 tumors at day 9 coincides with the increased PSA.
The CWR22 xenograft is derived from a patient’s primary tumor be-
ing androgen-sensitive [10,11,20], providing a valuable model of the
Figure 7. Triple immunofluorescent images showing vascular ar-
chitecture (9F1, red), perfused vessels (Hoechst 33342, blue), and
hypoxic areas (pimonidazole, green). These two images demon-
strate twodifferent hypoxia patterns: (A) hypoxia is evenly distributed
across the tumor; (B) hypoxia is more extensive and is constrain-
ing the vessels. When calculating hypoxic distance diagrams (dis-
tance hypoxia− blood vessels), this distance is less in panel B than
in panel A. The corresponding K trans values are 0.0184 ± 0.0004 ×
10−3 s−1 (A) and 0.0084 ± 0.0004 × 10−3 s−1 (B). HF indicates hyp-
oxic fraction (%); PVD, perfused vessel density (vessels/mm2); VD,
vessel density (vessels/mm2).
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clinical situation of localized PCa, because this xenograft model regresses
after ADTand shows stability before recurring growth in the androgen-
resistant state is evident. Although the androgen-deprivation response
characteristics of CWR22 xenografts seem to be representative of many
PCa, the heterogeneous clinical responses of human tumors should be
considered when making extrapolations. Notwithstanding, the parallels
between the CWR22 xenograft model and many human PCa suggest
that inferences based on the presented results apply to a significant pro-
portion of human PCa.
To summarize, we here present the radiation response of both
androgen-exposed and androgen-deprived CWR22 xenografts. Fur-
ther, we use in vivo DCE-MRI as a method, with the hemodynamic
transfer constant K trans as a biomarker, to noninvasively and repeatedly
assess tumor vascularization in these two phenotypes. The study
detected radiation-induced reductions of K trans values and tumor
volumes in androgen-exposed xenografts, whereas ADT induced sub-
stantially increased K trans values along with growth inhibition. No
significant additive effect of radiation was, however, seen in the
androgen-deprived xenografts. The presented results have encouraged
future expansion of the current study into more advanced stages of
PCa after ADT, also incorporating investigations of the role of hypoxia
in the transition from androgen-sensitive to androgen-resistant disease.
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